BLAINJECTIONINJECTABLE
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
BLENREP (belantamab mafodotin) by GSK. Approved for multiple myeloma, al amyloidosis, plasmablastic lymphoma and 2 more indications. First approved in 2025.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (5)
Worked on BLENREP at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.